HQY
HealthEquity, Inc. · NASDAQ · Healthcare · USD · 10-K for 2026, filed 2026-03-17
Figures on this page computed 2026-11-08 12:12 UTC
Last close
108.84USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2026, filed 2026-03-17
41.5xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
- computed
- 10-K for 2026, filed 2026-03-17
9.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
- 10-K for 2026, filed 2026-03-17
- 10-K for 2026, filed 2026-03-17
- 10-K for 2026, filed 2026-03-17
- 10-Q for 2026, filed 2026-08-27
- 10-K for 2026, filed 2026-03-17
- 10-Q for 2026, filed 2026-08-27
16.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
- 10-K for 2026, filed 2026-03-17
- 10-K for 2026, filed 2026-03-17
34.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
- 10-K for 2026, filed 2026-03-17
- 10-K for 2026, filed 2026-03-17
0.48Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
- 10-K for 2026, filed 2026-03-17
- 10-Q for 2026, filed 2026-08-27
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.22 against 0.36 on the market's range.
- Growth12.4%82 of 100, above its sector
- Returns on capital9.0%69 of 100, above its sector
- Margins69.5%87 of 100, above its sector
- Price41.5x22 of 100, below its sector
- Safety0.4865 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 3- Profit on each unit of sales16.4%-6.8%Ahead
Higher is better here.
- Return on the capital it uses9.0%n/an/a
Higher is better here.
- Sales growth over five years12.4%16.6%Behind
Higher is better here.
- Debt against equity0.48n/an/a
Lower is better here.
- Gross margin69.5%69.1%Ahead
Higher is better here.
- Price against earnings41.5xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against 10x Genomics, Inc., HQY is behind on 1 of 3 measures.
Against 10x Genomics, Inc., HQY is behind on 1 of 3 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2026, filed 2026-03-17
Profit on each unit of sales16.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
Return on the capital it uses9.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
Sales growth over five years12.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
Debt against equity0.48
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
Gross margin69.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD
Price against earnings41.5x
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001428336-26-000010
- Reported in
- USD